Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 2/20 | 0.40 |
| ▸ | DRD1 | P21728 | 2/20 | 0.40 |
| ▸ | DRD2 | P14416 | 13/20 | 0.39 |
| ▸ | HTR1A | P08908 | 10/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6472982 | 0.81 | HSD11B1 (0.40) | DRD3DRD2 | |
| SCHEMBL29118117 | 0.81 | DRD2 (0.43) | DRD3DRD1DRD2HTR1ACA1 | |
| SCHEMBL15511186 | 0.81 | ACE (0.42) | DRD3DRD1DRD2CA1CA2 | |
| SCHEMBL17559354 | 0.80 | ACE (0.46) | DRD3DRD2HTR1A | |
| SCHEMBL5243620 | 0.80 | ACE (0.46) | DRD3DRD2HTR1A | |
| SCHEMBL3898933 | 0.80 | ACE (0.46) | DRD3DRD2HTR1A | |
| SCHEMBL6504776 | 0.75 | CA2 (0.30) | CA2 | |
| SCHEMBL14061412 | 0.72 | RBP4 (0.35) | — | |
| SCHEMBL22319955 | 0.72 | DRD2 (0.41) | DRD1DRD2HTR1A | |
| SCHEMBL19284689 | 0.70 | ACE (0.41) | DRD3DRD1DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050153998-A1 | Tetrahydroisoquinoline or isochroman compounds | ITO FUMITAKA (JP) | 2005-07-14 | — | — | US | disclosed |
| WO-2005016913-A1 | TETRAHYDROISOQUINOLINE OR ISOCHROMAN COMPOUNDS AS ORL-1 RECEPTOR LIGANDS FOR THE TREATMENT OF PAIN AND CNS DISORDERS | PFIZER JAPAN, INC. (JP) | 2005-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050153998-A1 | Tetrahydroisoquinoline or isochroman compounds | OPRL1, NR1H3, HRH3 | DRD3 494/4885DRD1 365/4885DRD2 803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.